BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herbrink M, Nuijen B, Schellens JH, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 2015;41:412-22. [PMID: 25818541 DOI: 10.1016/j.ctrv.2015.03.005] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-01168-8] [Reference Citation Analysis]
2 Hu L, Cai M, Qian W, Dou T, Sun Q, Tang L, Wang H. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects. Invest New Drugs 2022. [PMID: 36087164 DOI: 10.1007/s10637-022-01299-3] [Reference Citation Analysis]
3 Rangaraj N, Sampathi S, Junnuthula V, Kolimi P, Mandati P, Narala S, Nyavanandi D, Dyawanapelly S. Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects. Pharmaceutics 2022;14:1807. [DOI: 10.3390/pharmaceutics14091807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Liao M, Zhou J, Wride K, Lepley D, Cameron T, Sale M, Xiao J. Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35844029 DOI: 10.1007/s13318-022-00773-w] [Reference Citation Analysis]
5 Verougstraete N, Stove V, Verstraete AG, Stove CP. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples. Front Oncol 2022;12:821807. [PMID: 35392223 DOI: 10.3389/fonc.2022.821807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Araujo-filho JAB, Mayoral M, Horvat N, Santini F, Gibbs P, Ginsberg MS. Radiogenomics in personalized management of lung cancer patients: Where are we? Clinical Imaging 2022. [DOI: 10.1016/j.clinimag.2022.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Libiad Y, Boutayeb S, Chaibi A. [Drug-drug interactions of tyrosine kinase inhibitors in treatment of non-small-cell lung carcinoma]. Bull Cancer 2022:S0007-4551(22)00010-8. [PMID: 35105467 DOI: 10.1016/j.bulcan.2021.11.019] [Reference Citation Analysis]
8 Koele SE, van Beek SW, van der Wekken AJ, Piet B, van den Heuvel MM, Ter Heine R. Pharmacokinetically-guided dosing to improve the efficacy of brigatinib in non-small cell lung cancer patients. Br J Clin Pharmacol 2021. [PMID: 34545619 DOI: 10.1111/bcp.15088] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Patel H, Wu ZX, Chen Y, Bo L, Chen ZS. Drug resistance: from bacteria to cancer. Mol Biomed 2021;2:27. [PMID: 35006446 DOI: 10.1186/s43556-021-00041-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Nicolò E, Trapani D, Berton Giachetti PPM, Zagami P, Curigliano G. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. Cancer Treat Rev 2021;100:102281. [PMID: 34500366 DOI: 10.1016/j.ctrv.2021.102281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lücking U, Kosemund D, Böhnke N, Lienau P, Siemeister G, Denner K, Bohlmann R, Briem H, Terebesi I, Bömer U, Schäfer M, Ince S, Mumberg D, Scholz A, Izumi R, Hwang S, von Nussbaum F. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer. J Med Chem 2021;64:11651-74. [PMID: 34264057 DOI: 10.1021/acs.jmedchem.1c01000] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
12 Mudie DM, Stewart AM, Rosales JA, Biswas N, Adam MS, Smith A, Craig CD, Morgen MM, Vodak DT. Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs. Pharmaceutics 2021;13:557. [PMID: 33921109 DOI: 10.3390/pharmaceutics13040557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Arzi RS, Kay A, Raychman Y, Sosnik A. Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing. Pharmaceutics 2021;13:529. [PMID: 33920184 DOI: 10.3390/pharmaceutics13040529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chen X, Xie B, Huang L, Wan J, Wang Y, Shi X, Qiao Y, Song H, Wang H. Quantitative self-assembly of pure drug cocktails as injectable nanomedicines for synergistic drug delivery and cancer therapy. Theranostics 2021;11:5713-27. [PMID: 33897877 DOI: 10.7150/thno.55250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Gong W, Yu J, Zheng T, Liu P, Zhao F, Liu J, Hong Z, Ren H, Gu G, Wang G, Wu X, Zhao Y, Ren J. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. Clin Transl Med 2021;11:e339. [PMID: 33634985 DOI: 10.1002/ctm2.339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chen X, Li Y, Yao T, Jia R. Benefits of Zebrafish Xenograft Models in Cancer Research. Front Cell Dev Biol 2021;9:616551. [PMID: 33644052 DOI: 10.3389/fcell.2021.616551] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Lavan M, Wang X, McCain R, Jannasch A, Cooper B, Hostetler S, Byrn S, Knipp G. Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies. AAPS PharmSciTech 2021;22:40. [PMID: 33417081 DOI: 10.1208/s12249-020-01891-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Skubalova Z, Rex S, Sukupova M, Zahalka M, Skladal P, Pribyl J, Michalkova H, Weerasekera A, Adam V, Heger Z. Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System. Int J Nanomedicine 2021;16:1-14. [PMID: 33442247 DOI: 10.2147/IJN.S275808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen X, Hu Z, Zhou L, Zhang F, Wan J, Wang H. Self-assembling a natural small molecular inhibitor that shows aggregation-induced emission and potentiates antitumor efficacy. Nanoscale Horiz 2021;6:33-42. [DOI: 10.1039/d0nh00469c] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021;11:1546-67. [PMID: 33408767 DOI: 10.7150/thno.48662] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
21 Roosendaal J, Rosing H, Beijnen JH. Combining Isotopic Tracer Techniques to Increase Efficiency of Clinical Pharmacokinetic Trials in Oncology. Drugs R D 2020;20:147-54. [PMID: 32300967 DOI: 10.1007/s40268-020-00304-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Zhao Y, Bilal M, Raza A, Khan MI, Mehmood S, Hayat U, Hassan STS, Iqbal HMN. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. Int J Biol Macromol 2021;168:22-37. [PMID: 33290765 DOI: 10.1016/j.ijbiomac.2020.12.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
23 Honeywell RJ, Kathmann I, Giovannetti E, Tibaldi C, Smit EF, Rovithi MN, Verheul HMW, Peters GJ. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers (Basel) 2020;12:E3322. [PMID: 33182766 DOI: 10.3390/cancers12113322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
24 Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SD. Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics 2020;12:E856. [PMID: 32916864 DOI: 10.3390/pharmaceutics12090856] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
25 Bruinsmann FA, Buss JH, Souto GD, Schultze E, de Cristo Soares Alves A, Seixas FK, Collares TV, Pohlmann AR, Guterres SS. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells. AAPS PharmSciTech 2020;21:229. [PMID: 32778976 DOI: 10.1208/s12249-020-01723-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Veerman GDM, Hussaarts KGAM, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol 2020;21:e265-79. [PMID: 32359502 DOI: 10.1016/S1470-2045(20)30069-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
27 Roosendaal J, Rosing H, Beijnen JH. Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology. Clin Pharmacol Drug Dev 2020;9:552-9. [PMID: 32573110 DOI: 10.1002/cpdd.840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Roosendaal J, Groenland SL, Rosing H, Lucas L, Venekamp N, Nuijen B, Huitema ADR, Beijnen JH, Steeghs N. Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose. Eur J Clin Pharmacol 2020;76:1075-82. [PMID: 32430518 DOI: 10.1007/s00228-020-02888-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Johne A, Scheible H, Becker A, van Lier JJ, Wolna P, Meyring M. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers. Invest New Drugs 2020;38:1507-19. [PMID: 32221754 DOI: 10.1007/s10637-020-00926-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
30 Vestri A, Pearce AK, Cavanagh R, Styliari ID, Sanders C, Couturaud B, Schenone S, Taresco V, Jakobsen RR, Howdle SM, Musumeci F, Sagnelli D. Starch/Poly(glycerol-adipate) Nanocomposites: A Novel Oral Drug Delivery Device. Coatings 2020;10:125. [DOI: 10.3390/coatings10020125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
31 Ezzeldin E, Iqbal M, Herqash RN, Elnahhas T. Simultaneous quantitative determination of seven novel tyrosine kinase inhibitors in plasma by a validated UPLC-MS/MS method and its application to human microsomal metabolic stability study. Journal of Chromatography B 2020;1136:121851. [DOI: 10.1016/j.jchromb.2019.121851] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
32 Kim SH, Suh Y, Ah YM, Jun K, Lee JY. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study. Support Care Cancer 2020;28:3617-26. [PMID: 31802250 DOI: 10.1007/s00520-019-05204-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
33 Gala UH, Miller DA, Williams RO 3rd. Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochim Biophys Acta Rev Cancer 2020;1873:188319. [PMID: 31678141 DOI: 10.1016/j.bbcan.2019.188319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
34 Stankevich KS, Schepetkin IA, Goreninskii SI, Lavrinenko AK, Bolbasov EN, Kovrizhina AR, Kirpotina LN, Filimonov VD, Khlebnikov AI, Tverdokhlebov SI, Quinn MT. Poly(ε-caprolactone) Scaffolds Doped with c-Jun N-terminal Kinase Inhibitors Modulate Phagocyte Activation. ACS Biomater Sci Eng 2019;5:5990-9. [DOI: 10.1021/acsbiomaterials.9b01401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
35 Zaritski A, Castillo-ecija H, Kumarasamy M, Peled E, Sverdlov Arzi R, Carcaboso ÁM, Sosnik A. Selective Accumulation of Galactomannan Amphiphilic Nanomaterials in Pediatric Solid Tumor Xenografts Correlates with GLUT1 Gene Expression. ACS Appl Mater Interfaces 2019;11:38483-96. [DOI: 10.1021/acsami.9b12682] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
36 Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-ribeiro AB, Xavier CP, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019;46:100645. [DOI: 10.1016/j.drup.2019.100645] [Cited by in Crossref: 81] [Cited by in F6Publishing: 159] [Article Influence: 27.0] [Reference Citation Analysis]
37 Groenland SL, Mathijssen RHJ, Beijnen JH, Huitema ADR, Steeghs N. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur J Clin Pharmacol 2019;75:1309-18. [PMID: 31175385 DOI: 10.1007/s00228-019-02704-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
38 Lin Q, Xie S, Qiu X, Chen J, Xu RA. Drug-drug interaction study of imatinib and voriconazole in vitro and in vivo. Infect Drug Resist 2019;12:1021-7. [PMID: 31118708 DOI: 10.2147/IDR.S199526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Williams HD, Ford L, Igonin A, Shan Z, Botti P, Morgen MM, Hu G, Pouton CW, Scammells PJ, Porter CJH, Benameur H. Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms. Adv Drug Deliv Rev 2019;142:75-90. [PMID: 31150666 DOI: 10.1016/j.addr.2019.05.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
40 de Man FM, Hussaarts KGAM, de With M, Oomen-de Hoop E, de Bruijn P, van Halteren HK, van der Burg-de Graauw NCHP, Eskens FALM, van Gelder T, van Leeuwen RWF, Mathijssen RHJ. Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study. Clin Pharmacol Ther 2019;105:1456-61. [PMID: 30570132 DOI: 10.1002/cpt.1331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
41 Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH. Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations. Mol Pharm 2018;15:5678-96. [PMID: 30376336 DOI: 10.1021/acs.molpharmaceut.8b00858] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
42 Zhang W, Fan YF, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P, Chen ZS. Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells. Front Pharmacol 2018;9:1097. [PMID: 30356705 DOI: 10.3389/fphar.2018.01097] [Cited by in Crossref: 23] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
43 de Gooijer MC, Buil LCM, Çitirikkaya CH, Hermans J, Beijnen JH, van Tellingen O. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. Mol Pharm 2018;15:5236-43. [PMID: 30252484 DOI: 10.1021/acs.molpharmaceut.8b00742] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kurniawan DW, Jajoriya AK, Dhawan G, Mishra D, Argemi J, Bataller R, Storm G, Mishra DP, Prakash J, Bansal R. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. J Control Release. 2018;288:227-238. [PMID: 30219279 DOI: 10.1016/j.jconrel.2018.09.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
45 Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Molecular Aspects of Medicine 2018;62:75-88. [DOI: 10.1016/j.mam.2017.11.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 100] [Article Influence: 18.8] [Reference Citation Analysis]
46 Maher HM, Alzoman NZ, Shehata SM. Ultra-performance LC–MS/MS study of the pharmacokinetic interaction of imatinib with selected vitamin preparations in rats. Bioanalysis 2018;10:1099-113. [DOI: 10.4155/bio-2018-0043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
47 Maher HM, Alzoman NZ, Shehata SM, Abanmy NO. Validated UPLC-MS/MS method for the quantification of dasatinib in plasma: Application to pharmacokinetic interaction studies with nutraceuticals in Wistar rats. PLoS One 2018;13:e0199208. [PMID: 29902246 DOI: 10.1371/journal.pone.0199208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
48 de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia 2018;20:710-20. [PMID: 29852323 DOI: 10.1016/j.neo.2018.05.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 42] [Article Influence: 8.5] [Reference Citation Analysis]
49 Herbrink M, Groenland SL, Huitema ADR, Schellens JHM, Beijnen JH, Steeghs N, Nuijen B. Solubility and bioavailability improvement of pazopanib hydrochloride. Int J Pharm 2018;544:181-90. [PMID: 29680279 DOI: 10.1016/j.ijpharm.2018.04.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
50 van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clin Pharmacokinet. 2017;56:683-688. [PMID: 28101705 DOI: 10.1007/s40262-016-0503-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
51 Chikhale R, Thorat S, Choudhary RK, Gadewal N, Khedekar P. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. Bioorg Chem 2018;77:84-100. [PMID: 29342447 DOI: 10.1016/j.bioorg.2018.01.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
52 Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed Chromatogr 2018;32. [PMID: 29165815 DOI: 10.1002/bmc.4147] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
53 Herbrink M, de Vries N, Rosing H, Huitema AD, Nuijen B, Schellens JH, Beijnen JH. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Ther Drug Monit 2016;38:649-56. [PMID: 27749781 DOI: 10.1097/FTD.0000000000000349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
54 Goodman AM, Neumann O, Nørregaard K, Henderson L, Choi MR, Clare SE, Halas NJ. Near-infrared remotely triggered drug-release strategies for cancer treatment. Proc Natl Acad Sci U S A 2017;114:12419-24. [PMID: 29109274 DOI: 10.1073/pnas.1713137114] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 8.4] [Reference Citation Analysis]
55 Jurj A, Braicu C, Pop LA, Tomuleasa C, Gherman CD, Berindan-Neagoe I. The new era of nanotechnology, an alternative to change cancer treatment. Drug Des Devel Ther 2017;11:2871-90. [PMID: 29033548 DOI: 10.2147/DDDT.S142337] [Cited by in Crossref: 71] [Cited by in F6Publishing: 79] [Article Influence: 14.2] [Reference Citation Analysis]
56 Gougis P, Wassermann J, Spano JP, Keynan N, Funck-Brentano C, Salem JE. Clinical pharmacology of anti-angiogenic drugs in oncology. Crit Rev Oncol Hematol 2017;119:75-93. [PMID: 28916378 DOI: 10.1016/j.critrevonc.2017.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
57 ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K. Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. Cancer Biol Ther 2016;17:1107-15. [PMID: 27415751 DOI: 10.1080/15384047.2016.1210733] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
58 Herbrink M, Schellens JHM, Beijnen JH, Nuijen B. Improving the solubility of nilotinib through novel spray-dried solid dispersions. Int J Pharm 2017;529:294-302. [PMID: 28689964 DOI: 10.1016/j.ijpharm.2017.07.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
59 Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. Br J Clin Pharmacol 2017;83:2195-204. [PMID: 28500677 DOI: 10.1111/bcp.13327] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
60 Herbrink M, Nuijen B, Schellens JH, Beijnen JH. High-Tech Drugs in Creaky Formulations. Pharm Res 2017;34:1751-3. [DOI: 10.1007/s11095-017-2185-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
61 Romero JE, Chiva JA, Peris-vicente J, Ochoa-aranda E. Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma. Bioanalysis 2017;9:799-812. [DOI: 10.4155/bio-2017-0028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
62 Scrivano L, Iacopetta D, Sinicropi MS, Saturnino C, Longo P, Parisi OI, Puoci F. Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation. Drug Deliv 2017;24:482-90. [PMID: 28181828 DOI: 10.1080/10717544.2016.1267822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
63 Herbrink M, Schellens J, Beijnen J, Nuijen B. Thermal study of pazopanib hydrochloride. J Therm Anal Calorim 2017;130:1491-9. [DOI: 10.1007/s10973-017-6286-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
64 Gay C, Toulet D, Le Corre P. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy: Pharmacokinetic interactions of TKIs. Hematological Oncology 2017;35:259-80. [DOI: 10.1002/hon.2335] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
65 Sawicki E, Schellens JH, Beijnen JH, Nuijen B. Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treat Rev 2016;50:247-63. [PMID: 27776286 DOI: 10.1016/j.ctrv.2016.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
66 Neul C, Schaeffeler E, Sparreboom A, Laufer S, Schwab M, Nies AT. Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends Pharmacol Sci 2016;37:904-32. [PMID: 27659854 DOI: 10.1016/j.tips.2016.08.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
67 von Richter O, Massimini G, Scheible H, Udvaros I, Johne A. Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients. Br J Clin Pharmacol 2016;82:1498-508. [PMID: 27483391 DOI: 10.1111/bcp.13078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
68 Herbrink M, Schellens JH, Beijnen JH, Nuijen B. Inherent formulation issues of kinase inhibitors. J Control Release 2016;239:118-27. [PMID: 27578098 DOI: 10.1016/j.jconrel.2016.08.036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
69 Sawicki E, Hillebrand MJ, Rosing H, Schellens JHM, Nuijen B, Beijnen JH. Validation of a liquid chromatographic method for the pharmaceutical quality control of products containing elacridar. J Pharm Anal 2016;6:268-75. [PMID: 29403992 DOI: 10.1016/j.jpha.2016.04.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Willemsen AE, Lubberman FJ, Tol J, Gerritsen WR, van Herpen CM, van Erp NP. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today 2016;21:962-76. [PMID: 26995271 DOI: 10.1016/j.drudis.2016.03.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
71 van Leeuwen RW, Peric R, Hussaarts KG, Kienhuis E, IJzerman NS, de Bruijn P, van der Leest C, Codrington H, Kloover JS, van der Holt B, Aerts JG, van Gelder T, Mathijssen RH. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol 2016;34:1309-14. [PMID: 26858332 DOI: 10.1200/JCO.2015.65.2560] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 11.3] [Reference Citation Analysis]
72 Gelderblom H, Köhne CH, Launay-Vacher V, van Leeuwen RW. Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists. Ann Oncol 2016;27:752. [PMID: 26787233 DOI: 10.1093/annonc/mdw019] [Reference Citation Analysis]
73 Francini CM, Fallacara AL, Artusi R, Mennuni L, Calgani A, Angelucci A, Schenone S, Botta M. Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors. ChemMedChem 2015;10:2027-41. [PMID: 26514807 DOI: 10.1002/cmdc.201500428] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
74 Musumeci F, Schenone S, Grossi G, Brullo C, Sanna M. Analogs, formulations and derivatives of imatinib: a patent review. Expert Opin Ther Pat 2015;25:1411-21. [PMID: 26372795 DOI: 10.1517/13543776.2015.1089233] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]